共 11 条
- [1] STUDIES ON CONDENSED PYRIMIDINE SYSTEMS .21. THE ISOLATION AND SYNTHESIS OF 6-MERCAPTO-2,8-PURINEDIOL (6-THIOURIC ACID)[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1959, 81 (12) : 3042 - 3045ELION, GBMUELLER, SHITCHINGS, GH
- [2] DEPLETION OF ERYTHROCYTE PHOSPHORIBOSYLPYROPHOSPHATE IN MAN - A NEWLY OBSERVED EFFECT OF ALLOPURINOL[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1970, 283 (22) : 1177 - &FOX, IHWYNGAARD.JBKELLEY, WN
- [3] LEVINE AS, 1969, CANCER CHEMOTH REP 1, V53, P53
- [4] QUANTITATION OF 6-MERCAPTOPURINE IN BIOLOGIC FLUIDS USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - A SELECTIVE AND NOVEL PROCEDURE[J]. JOURNAL OF CHROMATOGRAPHY, 1982, 230 (02): : 373 - 380NARANG, PKYEAGER, RLCHATTERJI, DC
- [5] POMALES R, 1963, BIOCHIM BIOPHYS ACTA, V72, P119
- [6] RAVIS W, 1984, BIOCH PHARM, V3, P443
- [7] EFFECTS OF ALLOPURINOL ON 6-MERCAPTOPURINE THERAPY IN NEOPLASTIC DISEASES[J]. ANNALS OF THE RHEUMATIC DISEASES, 1966, 25 (6S) : 655 - &RUNDLES, RW
- [8] VOGLER WR, 1973, AM J MED, V40, P548
- [9] VARIABLE BIOAVAILABILITY OF ORAL MERCAPTOPURINE - IS MAINTENANCE CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC-LEUKEMIA BEING OPTIMALLY DELIVERED[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (17) : 1005 - 1009ZIMM, SCOLLINS, JMRICCARDI, RONEILL, DNARANG, PKCHABNER, BPOPLACK, DG
- [10] INHIBITION OF 1ST-PASS METABOLISM IN CANCER-CHEMOTHERAPY - INTERACTION OF 6-MERCAPTOPURINE AND ALLOPURINOL[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (06) : 810 - 817ZIMM, SCOLLINS, JMONEILL, DCHABNER, BAPOPLACK, DG